The optimal therapeutic approach for young diffuse large B-cell lymphoma (DLBCL) patients with high-intermediate and high-risk age-adjusted international prognostic index (aaIPI) remains unknown. Hereby we report a 10-year single-centre study of 63 consecutively treated patients. To optimize outcome, two approaches were carried out: Cohort 1 patients received four cycles R-CHOP-21 (rituximab, cyclophosphamide, daunorubicin, vincristine, prednisolone over 21 days) followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT), resulting in 2-year progression-free (PFS) and overall survival (OS) of 60Á6% and 67Á9%. 39Á4% of those patients were not transplanted upfront, mainly due to early progressive disease (24Á2%). Cohort 2 patients received an early intensified protocol of six cycles of CHOP-14 (cyclophosphamide, daunorubicin, vincristine, prednisolone over 14 days) with dose-dense rituximab and high-dose methotrexate resulting in promising overall response-(93Á3%) and complete remission (90%) rates and sustained survival (2-year PFS and OS: 93Á3%). In an intention-to-treat analysis, 2-year PFS (60Á6% vs. 93Á3%, hazard ratio [HR] 7Á2, P = 0Á009) and OS (69Á7% vs. 93Á3%, HR 4Á95, P = 0Á038) differed significantly, in favour of the early intensified protocol (Cohort 2). In a multivariate Cox-regression model, PFS (HR 8Á12, 95% confidence interval [CI] 1Á83-35Á9, P = 0Á006) and OS (HR 5Á86, 95% CI 1Á28-26Á8, P = 0Á02) remained superior for Cohort 2 when adjusted for aaIPI3 as the most important prognostic factor. Survival of young poor-prognosis DLBCL patients appears superior after early therapy intensification.
Despite major improvements in treatment for diffuse large B-cell lymphoma (DLBCL), around 25% of young high risk patients (age-adjusted international prognostic index [aaIPI] 2/3) still have a poor prognosis Schmitz et al, 2012a) . Following the addition of rituximab to standard CHOP 14 (cyclophosphamide, daunorubicin, vincristine, prednisolone) therapy, outcomes have improved significantly in good-risk DLBCL patients (Pfreundschuh et al, 2011) . To further improve outcomes in young poor-prognosis patients, several approaches have been investigated. While dose intensification with autologous stem cell transplantation (ASCT) is already a standard treatment modality for relapsed DLBCL (Philip et al, 1995) , recent clinical trials addressed the idea of an upfront ASCT approach. In the pre-rituximab era, high-dose treatment with ASCT was superior to CHOP treatment (Milpied et al, 2004) . However, large clinical trials revealed no improvement in overall survival (OS) compared to R-CHOP Stiff et al, 2013) . Dose escalation of cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) with rituximab and repetitive stem cell support (R-megaCHOEP) appears inferior to standard dose R-CHOEP. Of note, aaIPI 2/3 patients experienced a 3-year OS of 84Á6% with standard R-CHOEP (Schmitz et al, 2012a ). In conclusion, previous studies have failed to prove the benefit for using early dose intensified chemotherapy with ASCT as treatment for poorprognosis patients.
Poor-prognosis (aaIPI 2/3) patients presenting at Freiburg University Medical Centre from 2005 to 2011 were scheduled to receive HDCT/ASCT as first-line treatment. Patients aged 18-60 years underwent induction with R-CHOP-21, followed by two cycles of R-VCPE (rituximab, etoposide, cyclophosphamide, cisplatin, epirubicin), stem cell collection and upfront HDCT with BEAM (carmustine, etoposide, cytarbine, melphalan) and ASCT.
With the results that emerged from the Groupe Ouest Est d'Etude des Leuc emies et Autres Maladies du Sang (GOE-LAMS) 075 trial and preliminary evaluation of our data, the Comprehensive Cancer Centre Freiburg (CCCF) guidelines were altered in 2011: An early intensified treatment protocol consisting of six cycles CHOP-14, incorporating dose-dense rituximab [as suggested by data from the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) trials (Murawski et al, 2014; Pfreundschuh et al, 2014a,b,c) ] and high-dose methotrexate (MTX) as primary intensification, and central nervous system (CNS)-directed approach, was designed.
Patients and methods

Patients and eligibility
The CCCF patient database was searched and records reviewed to identify all consecutive patients from 2005 to 2015 that fulfilled the following criteria: Age 18-60 years (cohort 1) and 18-70 years (cohort 2), de novo biopsy-proven diagnosis of DLBCL and poor-prognosis features: aaIPI 2/3 with or without site-specific risk factors for CNS disease or aaIPI 1 with site-specific risk factors for CNS disease (testicular lymphoma, renal and adrenal involvement or orbital affection) (Villa et al, 2010) . There were no exclusion criteria except primary CNS disease. Patients with primary mediastinal lymphoma (PMBL) were not included in the analysis. Patients who could not be treated according CCCF guidelines received the best available standard of care and were similarly followed-up.
Staging procedures
Standard staging procedures included medical history, physical examination, performance status according to the Eastern Cooperative Oncology Group (ECOG) scale, routine laboratory tests including lactate dehydrogenase (LDH), chest and abdominal computed tomography (CT) scans and bone marrow biopsy. Further investigations, such as cytology or fluorescence-activated cell sorting analysis of pleural or cerebrospinal fluid, were performed in case of clinically suspected involvement. Fluorescence in situ hybridisation and immunohistochemistry for MYC, BCL2 and BCL6 breakpoints and overexpression were not routinely performed. Routine response assessment was done according to the standardized response criteria (Cheson et al, 1999 (Cheson et al, , 2007 . Final response analyses was done according to the revised Lugano criteria (Cheson et al, 2014) . Response assessment was done six to twelve weeks after completion of the planned treatment.
Study design and treatment modalities
Two sequential CCCF treatment approaches were identified. Cohort 1: From 2005 to 2011 patients were intended for HDCT/ASCT first-line treatment. They underwent four cycles of standard dose R-CHOP-21. Two patients received 6 weeks VACOP-B (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisolone, bleomycin) (O'Reilly et al, 1991) induction with an additional six cycles of rituximab and subsequent treatment as described below. Peripheral stem cell collection was performed as described previously (Bertz et al, 2004) Patients with bulky disease, defined as any mass of 7Á5 cm or larger at the largest diameter, were to receive consolidation radiotherapy. In both cohorts, infection prophylaxis via trimethoprim/sulfamethoxazole and aciclovir was routinely given. Further treatment in both cohorts was guided by the attending physician's decision.
Adverse events were retrospectively evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (http://ctep.cancer.gov/protocolDevelopment/e lectronic_applications/docs/ctcaev3.pdf) for leucocytopenia, thrombocytopenia, anaemia, serum creatinine levels, serum bilirubin levels, infections and mucositis.
All patients gave written informed consent prior to treatment onset. The study was approved by the Ethics Committee at the University Freiburg (registration number 11/16) and registered in World Health Organisation Trial Registration (DRKS00009982).
Statistical analysis
Statistical analyses were conducted with GraphPad Prism 5 â (GraphPad Software Inc., La Jolla, CA, USA) and SAS v9.2 (SAS Institute Inc., Cary, NC USA). OS was calculated from initial diagnosis until death from any cause. Progression-free survival (PFS) was defined as time from initial diagnosis until disease progression or death from any cause. Patients for whom the event of interest was not observed were censored on the date of their last follow-up visit. OS and PFS rates were estimated using the Kaplan-Meier method. Survival distributions were compared using uni-and multivariate Cox proportional hazards regression models. We report hazard ratios (HR) with accompanying two-sided 95% confidence intervals (CI). In order to evaluate differences between treatment cohorts we first determined the frequencies of patient characteristics (Table I ) and compared these using chi-square tests. Further, we applied multivariate Cox models to assess the impact of treatment type (Cohort 1 or 2) on PFS and OS when adjusting for known prognostic factors. As the number of patients and events is limited and prognostic variables are interrelated, we used several bivariate models, adjusting the treatment comparison for one prognostic variable at a time. Statistical significance was defined as P ≤ 0Á05. Treatment comparisons were performed according to an intention-to-treat (ITT) approach, i.e. all patients identified fulfilling the inclusion criteria were included in the analyses in order to avoid a selection bias.
Results
Patient characteristics
Sixty-three patients were identified and evaluated according to their basic disease characteristics (Table I) , treatment modalities and treatment outcome. The median follow-up was 35Á5 months. Two sequential treatment approaches were carried out at CCCF from 2005 to 2015. The basic characteristics were well balanced in both treatment cohorts: median age was 48 years in Cohort 1 and 53 years in Cohort 2. Histology was DLBCL with one human immunodeficiency virus-associated plasmoblastic lymphoma in each group and one follicular lymphoma grade IIIb in Cohort 2. Most patients had disease stage III/IV (97% vs. 86Á6%), high-intermediate (81Á8% vs. 66Á7%) or high-risk aaIPI score (18Á2% vs. 26Á6%). LDH was elevated in all patients. 30% of patients in each cohort had bulky disease. 21Á2% in Cohort 1 and 36Á7% in Cohort 2 had ECOG performance status ≥2. There was no significant difference in the distribution of baseline variables. 
Treatment modalities
Cohort 1: From 2005 to 2011, 33 patients were intended for first-line HDCT/ASCT treatment, of whom 13 (39Á4%) failed to complete the protocol. Reasons for not completing the protocol were progressive disease (PD) during induction therapy in eight individuals (24Á2%), treatmentrelated death during induction therapy in three patients (9%) (two of those died of infectious complications and one patient died of intracranial bleeding). Two patients (6%) refused primary intensification with R-VCPE and HDCT/ASCT and received six and eight cycles of standard R-CHOP-21 instead. Initial patient characteristics did not differ between those with early PD or those with sustained responses.
Cohort 2: Six (20%) of the 30 patients identified did not undergo the early-intensified protocol. High-dose MTX was not administered in two patients with chronic kidney disease and one patient with prior allogeneic kidney transplantation. One patient had proven double hit lymphoma, and two refused. Of those six patients, three received R-CHOP-21 for six cycles plus two cycles of rituximab, and the other three underwent primary intensification with HDCT/ASCT after R-CHOP-21 induction. These six patients were similarly followed-up and included in the intention-to-treat analysis. 22 T. Str€ ußmann et al out of 24 patients (91Á7%) completed the early-intensified protocol.
Response assessment and survival analyses
The OS and PFS at 2 years for the entire cohort were 81% [95% CI 71Á1-90Á9%] and 76% [95% CI 65Á4-86Á6%] (Fig 2A) . In Cohort 1, the overall response rate (ORR) was 66Á7% with a complete remission rate (CRR) of 63Á6% (Table II) . PD occurred early in the disease course [on average 145 days after diagnosis (range 61-210)]. All patients with PD received second-line therapy (n = 8) and six of them were bridged to HDCT/ASCT. One patient underwent allogeneic transplantation. Three of the eight PD patients achieved sustained responses. Of those with progressive or relapsed disease, five patients (62Á5%) had CNS involvement. With a median follow-up of 64Á7 months (Interquartile range (IQR) 15Á5-88Á1) for Cohort 1, 2-year PFS was 60Á6% [95% CI 43Á9-77Á3%] and 2-year OS was 69Á7% [95% CI 54-85Á4%] (Fig 2B) . Patients who completed therapy (n = 20) revealed favourable outcomes, with a CRR of 95% and a 2-year PFS and OS of 95% [95% CI 85Á4-100%], respectively. Two relapses were observed in that group (at 10 months and 3Á4 years after diagnosis). Patients who could not complete therapy had a significantly worse outcome: there were two complete remissions after first-line treatment (15Á4%) and a 2-year PFS of 7Á7% [95% CI 0-22Á2%] and 2-year OS of 30Á8% [95% CI 5Á8-55Á8%]. Median PFS was 5 months. Causes of death are summarized in Table SI . Of note, one patient with confirmed double hit lymphoma completed the protocol and achieved sustained complete remission.
Cohort 2: ORR was 93Á3% with a CRR of 90% (Table III) . Three patients had positive positron emission tomography/ CT scan according to the revised Lugano criteria (Cheson et al, 2014) . Of the three re-biopsies done, two were negative for lymphoma and one revealed residual lymphoma. Seven patients received consolidation radiotherapy and two patients received HDCT/ASCT for consolidation, in line with the attending physician's decision. The patient with biopsy-proven residual lymphoma underwent radiotherapy. There was one early death from autopsy-proven lymphoma infiltration of the heart and consecutive arrhythmia on treatment day four. One patient failed to complete the protocol due to severe sepsis before the 6th CHOP cycle. Another patient who presented evidence of a double hit constellation on retrospective evaluation had PD with CNS manifestation shortly after completing therapy and immediately before final re-staging. This patient did not respond to either second or third-line treatment with R-MTX/cytarabine and R-DeVIC (rituximab, dexamethasone, etoposide, ifosfamide, carboplatin) (Motomura et al, 2011) and died 8Á6 months after the diagnosis (Table SI) . With a median follow-up of 27Á9 months, IQR (19Á3-36Á2) for Cohort 2, we observed no relapses. Estimated 2-year PFS and OS were 93Á3% [95% CI 84Á4-100%], respectively (Fig 2B) . A median of 96% of planned therapy cycles was administered. No treatment-related deaths were observed.
Survival comparison
In an intention-to-treat analysis that compared cohorts 1 and 2, there was significant difference in 2-year PFS (60Á6% vs. 93Á3%, HR 7Á2 95% CI 1Á64-31Á75 P = 0Á009) and OS (69Á7% vs. 93Á3%, HR 4Á95, 95% CI 1Á09-22Á4, P = 0Á038) in favour of the early intensified protocol (Cohort 2). In a multivariate Cox regression model, treatment cohort analysis demonstrated a significantly inferior PFS (HR 8Á12, 95% CI 1Á83-36, P = 0Á006) and OS (HR 5Á86, 95% CI 1Á28-26Á8, P = 0Á02) for patients treated in Cohort 1 when adjusting for high-risk aaIPI (3) as the most important known prognostic factor (Table IV) . Similarly, adjusting the treatment cohort comparison for other factors in turn (Stage, age ≥ 50 years, extranodal site involvement or bone marrow involvement) did not change the results substantially (Table SII) .
Toxicities
In Cohort 1, we observed treatment-related death in 9% of patients, all of which were during R-CHOP-21 induction therapy. We observed no transplant-related mortality. Haematological toxicities and infections occurred frequently, as expected with HDCT-ASCT treatment. No treatment-related deaths were observed in Cohort 2. Mucositis occurred frequently. Renal toxicity occurred in 20% of Cohort 2 patients (CTCAE grade 1 and 2); however serum creatinine elevation was transient and reversible. There was no serum creatinine elevation CTCAE grade ≥ 3 (Table SIII) .
Discussion
The survival of young poor prognosis DLBCL patients has improved in the rituximab era. To date, R-CHOEP treatment led to 3-year PFS and OS of 73Á7% and 84Á6%, respectively (Schmitz et al, 2012a) . In this single centre, retrospective study R-CHOP-21 induction followed by HDCT-ASCT led to 2-year PFS and OS of 60Á6% and 69Á7%, respectively (Cohort 1). A substantial number of Cohort 1 patients experienced only a brief PFS, mainly due to PD early in the disease course. We did not assess whether those particular patients were in a CR, complete remission; CT, computed tomography; ORR, overall response rate; PD, progressive disease; PET, positron emission tomography; PR, partial remission; SD, stable disease. *According to Cheson et al (2014) . biologically high-risk group involving the presence of MYC and BCL2 translocations (Johnson et al, 2009) or overexpression (Horn et al, 2013) , or were characterized by geneexpression profiling (GEP) (Guti errez-Garc ıa et al, 2011). Implementation of the early-intensified protocol (Cohort 2), did not produce an early drop in PFS and OS, resulting in an encouraging CR rate of 90% and 2-year PFS and OS of 93Á3%, respectively. Our results indicate a significant reduction of primary progressive and refractory disease for poor prognosis patients treated with early dose-dense and intensified immune-chemotherapy. Notably, we attempted to treat all our consecutive patients via the early-intensified protocol to avoid a selection bias. All the patients unable to be treated according to CCCF guidelines were similarly followed up and included in the analysis. Recent evidence indicates that standard dose rituximab may not suffice in older men and younger patients (Pfreundschuh et al, 2014a) . DSHNHL Phase II studies yielded controversial data: while increasing the rituximab dose to 500 mg/m 2 equalized the prognosis of older men and women in the SEXIE-R-CHOP trial (Pfreundschuh et al, 2014c) , the application of dose-dense rituximab in the DENSE-R-CHOP-14 trial resulted in better response rates but not better outcomes (Murawski et al, 2014) . The SMARTE-R-CHOP-14 trial reported significantly better outcomes in elderly poor-prognosis patients in conjunction with extended rituximab application (Pfreundschuh et al, 2014b) . Recent preliminary results from the dense-R-CHOEP trial revealed no significant difference in PFS or OS for young poor-prognosis patients receiving dose-dense rituximab compared to standard treatment. Interestingly, aaIPI 3 patients did better than expected; however, no significant difference was detected . To optimize rituximab exposure, we integrated a dose-dense schedule in the early-intensified protocol (Cohort 2). High-dose MTX was incorporated to provide an effective CNS prophylaxis in this patient group at high risk for CNS relapse (Schmitz et al, 2012b) and moreover to enable increased systemic anti-lymphoma activity early in the disease course. In a retrospective series published by Abramson et al (2010) , high-dose MTX was effective in reducing CNSrelapse rate. A multicentre analysis provided similar data (Cheah et al, 2014) : administering 2-3 cycles of high-dose MTX (1-3Á5 g/m 2 ) led to CNS relapse rates ranging from 3% to 6Á9%. MTX is also an highly active drug in primary CNS lymphoma (PCNSL) (Illerhaus et al, 2006) and is widely used to treat acute lymphoblastic leukaemia (Hoelzer et al, 1996) . There is recent evidence of improved PFS and OS for poor prognosis patients when treated with high-dose MTX/cytarabine-based regimens (Dann et al, 2015; Mel en et al, 2016) .
Our study provides limited evidence regarding the efficacy of MTX as CNS prophylaxis due to our low patient numbers. One patient in Cohort 2 developed a CNS relapse (3Á3%) after two courses of high-dose MTX. As CNS relapses usually occur during the first six months after diagnosis, a significant percentage of patients may already have subclinical CNS involvement at the time of diagnosis (Bernstein et al, 2009) . Therefore, high dose MTX administered earlier in the course of the disease may be more efficient. Five patients in Cohort 1 (15%) had secondary CNS manifestation; one of whom had undergone HDCT/ASCT as first-line treatment.
The data is inconclusive on administering (R-)CHOP in a two or three weekly manner (R-CHOP-14/-21). In the pre-rituximab era, CHOP-14 achieved higher CR rates than CHOP-21 (Pfreundschuh et al, 2004) , although larger prospective trials failed to demonstrate a benefit (Cunningham et al, 2013) . As R-CHOP-14 and -21 achieved equal results in prior studies, we opted for six cycles of CHOP-14.
Patients with bulky disease were not routinely treated with consolidation radiotherapy (two of ten in Cohort 1, and three of nine in Cohort 2). Results of a planned interim analysis of the UNFOLDER trial (NCT00278408) suggest a benefit of additional radiotherapy to bulky disease; the inhomogeneity in our cohorts may influence the reported survival data.
Integrating etoposide with standard CHOP improved outcome in young low-risk DLBCL patients (Pfreundschuh et al, 2004) . Furthermore, response rates significantly improved in younger ALK-positive anaplastic large cell lymphoma patients, and it also tended to be better in other T-cell lymphoma subtypes (Schmitz et al, 2010) . Results of the mega-CHOEP trial indicate the efficacy of integrating etoposide with R-CHOP in young poor prognosis DLBCL patients (Schmitz et al, 2012a) . Whether etoposide as a component in the HDCT/ASCT approach (Cohort 1), has influenced the reported outcome remains unknown.
To summarize, this population-based retrospective study indicates a favourable outcome in poor prognosis patients treated with an early-intensified approach. After having implemented our early-intensified protocol (Cohort 2), 93Á3% of patients responded and have maintained sustained remissions with encouraging survival data in this poor prognosis DLBCL patient cohort. Nevertheless, longer follow-up periods and larger patient cohorts are warranted. Given the limitations of this retrospective comparison, randomized controlled studies are necessary to further investigate our early-intensified approach. Moreover, with deeper insights into lymphoma biology (Horn et al, 2015) , the role of emerging small molecule inhibitors of BCL2 and MYC in combination with immune-chemotherapy needs to be investigated. 
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